Discover trends, market shifts, and competitive outlooks for the antidiabetics industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Antidiabetics Market Size Shifted, And What Is the Outlook Through 2034?

In recent times, the antidiabetics market has witnessed substantial expansion. It is anticipated to rise from the 2024 market value of $76.03 billion to $84.84 billion in 2025 with a compound annual growth rate (CAGR) of 11.6%. Factors attributing to this increase during the historic period include the surge in global diabetes incidence, advances in medication development, heightened awareness, wider diagnosis, beneficial governmental strategies, an aging population, inactive lifestyles, and escalating healthcare spending.

The market size for antidiabetics is anticipated to experience a substantial surge in the upcoming years, escalating to $130.12 billion by 2029, with a compound annual growth rate (CAGR) of 11.3%. Factors contributing to this expansion in the predicted period include the rising incidents of diabetes, enhanced awareness and diagnosis, growth in healthcare spending, the increase in the elderly population, and initiatives and health policies implemented by the government. Key trends during this forecast period encompass the expansion of GLP-1 receptor agonists and SGLT2 inhibitors, proliferation of biologics and biosimilars, emphasis on preventive healthcare, growth in emerging markets, and integration of advanced technology.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18225&type=smp

Which Factors and External Forces Are Driving Demand in the Antidiabetics Market?

The growth of the antidiabetics market is forecasted to be propelled by the escalating prevalence of conditions related to unhealthy lifestyles. Lifestyle-associated health issues stem from or are worsened by harmful habits such as inadequate diet, sedentary behavior, smoking, and heavy drinking. With unhealthy diets, lack of physical activity, and heightened stress levels on the rise, so is the prevalence of these lifestyle-related conditions. Antidiabetic drugs can aid in managing these lifestyle-related disorders, such as obesity and metabolic syndrome, by enhancing insulin sensitivity and regulating glucose levels in the blood. For example, the World Health Organization, headquartered in Switzerland, reported in March 2022 that about 1 billion people globally, including 650 million adults, 340 million teens, and 39 million children, are obese. This figure continues to climb. By 2025, it’s projected that 167 million adults and children will experience health issues due to overweight or obesity. Therefore, the escalating prevalence of lifestyle-implicated conditions is fueling the expansion of the antidiabetic market.

Which Segments in the Antidiabetics Offer the Most Growth?

The antidiabetics market covered in this report is segmented –

1) By Drug Class: Insulin, GLP-1 Receptor Agonists, DPP- 4 Inhibitors, SGLT2 Inhibitors, Other Drug Classes,

2) By Diabetes Type: Type 1, Type 2

3) By Patient Population: Antidiabetics For Pediatrics, Antidiabetics For Adults, Antidiabetics For Geriatrics

4) By Route Of Administration: Antidiabetics Administration Through Insulin Syringes Or Insulin Pens, Antidiabetics Administration Through Insulin Pumps, Intravenous Antidiabetics Infusion, Oral Antidiabetics Administration, Other Routes Of Antidiabetics Administration

5) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

Subsegments:

1) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin

2) By GLP-1 Receptor Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide

3) By DPP-4 Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin

4) By SGLT2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin

5) By Other Drug Classes: Sulfonylureas, Thiazolidinediones (TZDs), Alpha-Glucosidase Inhibitors, Meglitinides, GLP-1/Insulin Combination Therapy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=18225&type=smp

What Are the Fastest-Growing Geographies in the Antidiabetics Market?

North America was the largest region in the antidiabetics market in 2023. The regions covered in the antidiabetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Antidiabetics Market?

Leading firms in the antidiabetics market are introducing innovative products like anti-diabetic biosimilars intended to enhance glycemic regulation, mitigate the probability of cardiovascular incidents, and provide more efficient treatment solutions for people suffering from diabetes. An anti-diabetic biosimilar is a bioequivalent drug to a previously sanctioned reference product used in diabetes treatment with similar safety, efficacy, and quality. For example, Glenmark Pharmaceuticals Limited, a pharmaceutical firm based in India, introduced the first biosimilar of Liraglutide, a medication for diabetes, in January 2024. The biosimilar version of the Liraglutide anti-diabetic drug, marketed as Lirafit, ameliorates glycemic management in adults diagnosed with type 2 diabetes mellitus. Clinical studies indicate that it decreases glycemic parameters, assists in weight reduction, and promotes cardiovascular safety. As a GLP-1 receptor stimulant, it heightens glucose-responsive insulin secretion and curbs improper glucagon secretion. It has worldwide approval for controlling type 2 diabetes in adults.

View the full report here:

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

What Are the Key Elements That Define the Antidiabetics Market?

Antidiabetics are a class of medications used to treat diabetes mellitus, a condition characterized by high blood glucose levels. These medications help control blood sugar levels in various ways, depending on the type of diabetes and the mechanism of the drug. Antidiabetics manage blood sugar levels, reduce complications, improve health outcomes, enhance metabolic control and insulin sensitivity, offer customized treatment options, and provide additional benefits such as weight management and cardiovascular protection.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18225

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model